LETTERS TO THE EDITOR

Paternal and maternal transmission of pseudohypoparathyroidism type Ia in a family with Albright hereditary osteodystrophy: no evidence of genomic imprinting

Albright hereditary osteodystrophy (AHO) is a rare autosomal dominant disorder characterised by short stature, obesity, round facies, subcutaneous calcifications, and characteristic skeletal defects.¹ Pseudohypoparathyroidism type Ia (PHP-Ia) is AHO with resistance to parathyroid hormone (PTH) and other hormones acting via cyclic adenosine monophosphate (cAMP) in the presence of reduced G_s protein. AHO alone (without hormone resistance) has been classified as pseudopseudohypoparathyroidism (PPHP).² Several heterozygous mutations within the gene encoding the α subunit of the G protein (GNAS1), which stimulates the adenylyl cyclase, have been identified in patients with AHO,^{3,4} whether they were affected by PHP-Ia or PPHP.

After reviewing published reports of 31 AHO kindreds, it has been recently suggested that genomic imprinting may be involved in the differing phenotypic expression: in all families studied so far PHP was solely maternally inherited, whereas PPHP was transmitted by the father.⁵

We recently reported on a family with AHO and reduced GNAS1 activity.⁶ The pedigree of this family is shown in the figure. One male infant (IV-3) was affected by PHP-

Ia and four family members (II-6, III-2, III-3, and III-5) had PPHP.⁶ A female infant (IV-1) was born to a healthy mother (III-1) and a father affected by PPHP (III-2). During the first year of life several subcutaneous nodules (osteoma cutis) developed on the child's back and left arm. So far serum calcium, parathyroid hormone (PTH), free triiodothyronine (FT3), free thyronine (FT4), and thyrotropin (TSH) are normal, but phosphorus has gradually risen to 9.3 mg/dl (normal 5 to 8 mg/dl). At the age of 14 months a modified Ellsworth-Howard test was performed.⁷ Injection of synthetic 1-38 hPTH resulted in a blunted response of plasma cAMP (basal 23.2 nmol/l, after five minutes 29.0 nmol/l, after 10 minutes 21.0 nmol/l; normal > 100 nmol/l after five or 10 minutes) and urinary cAMP (basal 3.6 nmol/dl glomerular filtrate, after 90 minutes 3.4 nmol/dl glomerular filtrate; normal > 60 nmol/dl glomerular filtrate). The tubular reabsorption of phosphate (TRP) did not decrease after injection of PTH. Injection of thyrotropin releasing hormone (TRH) resulted in an exaggerated response of TSH (basal 3.0 mU/l, after 30 minutes 28.6 mU/l; normal 3 to 25 mU/l after 30 minutes). Therefore, the diagnosis of normocalcaemic PHP-Ia was made.

A similar pattern of hormone unresponsiveness has been found in the other patient with PHP-Ia (IV-3) at the age of 10 years. In addition, this child also exhibited hypocalcaemia and hyperphosphataemia and serum PTH was increased (230 pg/ml, normal 15 to 55 pg/ml).⁶

All patients with PPHP (III-2, III-3, and III-5) showed a normal increase of cAMP after injection of 1-38 hPTH.⁶

The results show that PHP-Ia can be inherited paternally as well as maternally, suggesting that mechanisms other than genomic imprinting are responsible for the full expression of hormone resistance, at least within this family. It has been suggested by others that additional components of the G_s coupled signal transduction (for example, calmodulin, cAMP phosphodiesterase, protein kinase A) may be responsible for the difference between PHP-Ia and PPHP.⁸

Recently, a proximal 15q chromosomal

deletion was detected in a female with PHP-Ia as well as in her mother, who also had PHP-Ia.⁹ Molecular analyses with 10 different DNA markers from this region did not detect any uniparental disomy or deletion.

Further studies are needed to clarify whether genomic imprinting (especially within the region 20q12-q13.2, which includes the locus for GNAS1¹⁰) accounts for variable expression of AHO in most affected families.

VOLKER SCHUSTER

Children's Hospital,
University of Würzburg,
97080 Würzburg, Germany.
WOLFRAM KRESS
Department of Human Genetics,
University of Würzburg,
97074 Würzburg, Germany.
KLAUS KRUSE
Children's Hospital,
Medical University of Lübeck,
23562 Lübeck, Germany.

- Albright F, Burnett CH, Smith PH, Parson W. Pseudohypoparathyroidism - an example of 'Seabright-Bantam syndrome'. *Endocrinology* 1942;30:922-32.
- Albright F, Forbes AP, Henneman PH. Pseudopseudohypoparathyroidism. *Trans Assoc Am Physicians* 1952;65:337-50.
- Weinstein LS, Gejman PV, Friedman E, et al. Mutations in the G_s -subunit gene in Albright hereditary osteodystrophy detected by denaturing gradient gel electrophoresis. *Proc Natl Acad Sci USA* 1990;87:8287-90.
- Weinstein LS, Gejman PV, de Mazancourt P, American N, Spiegel AM. A heterozygous 4-bp deletion mutation in the G_s gene (GNAS1) in a patient with Albright hereditary osteodystrophy. *Genomics* 1992;13:1319-21.
- Davis SJ, Hughes HE. Imprinting in Albright's hereditary osteodystrophy. *J Med Genet* 1993;30:101-3.
- Schuster V, Eschenhagen T, Kruse K, Gierschik P, Kreth HW. Endocrine and molecular biological studies in a German family with Albright hereditary osteodystrophy. *Eur J Pediatr* 1993;152:185-9.
- Kruse K, Kracht U. A simplified diagnostic test in hypoparathyroidism and pseudohypoparathyroidism type I with synthetic 1-38 fragment of human parathyroid hormone. *Eur J Pediatr* 1987;146:373-7.
- Spiegel AM. Albright's hereditary osteodystrophy and defective G proteins. *N Engl J Med* 1990;322:1461-2.
- Hedeland H, Berntorp K, Arheden K, Kristoffersson U. Pseudohypoparathyroidism type I and Albright's hereditary osteodystrophy with a proximal 15q chromosomal deletion in mother and daughter. *Clin Genet* 1992;42:129-34.
- Rao VV, Schnitter S, Hansmann I. G protein G_s (GNAS1), the probable candidate gene for Albright hereditary osteodystrophy, is assigned to human chromosome 20q12-q13.2. *Genomics* 1991;10:257-61.

Severe pulmonary and digestive disease in a cystic fibrosis child homozygous for G542X

In southern France, the G542X mutation,¹ in which the glycine (GCA) at amino acid position 542 in exon 11 is mutated to a stop codon (TGA), accounts for 5-6% of the CF chromosomes² and represents the second most frequent CF mutation in this population after the deletion $\Delta F508$. In a sample of 150 patients who have been genotyped for CFTR mutations (unpublished results), we identified only one patient with two 542X alleles. In contrast to other reports on homozygous nonsense mutations³⁻¹⁰ describing mild expression of the disease, the 6 year old girl presented here has been severely affected since infancy.

The patient is the youngest of two sibs born to healthy, unrelated patients originat-

Family pedigree.

ing from Murcia, Spain. She was born in 1987, without meconium ileus, and was diagnosed as having cystic fibrosis at the age of 5 months, on the basis of growth retardation, gastrointestinal problems (especially diarrhoea and steatorrhoea), and repeated bronchitis. *Staphylococcus aureus* then *Pseudomonas aeruginosa* have been found in the patient's sputum since she was 6 months old. She is treated with pancreatic enzymes and antibiotics, but her obstructive lung disease has increased and the patient is classified as severely affected by the clinicians.

Using the SSCP technique¹¹ to study the DNA extracted from the patient and her family, we detected then identified the stop mutation G542X in the two CFTR genes transmitted to the affected child. This mutation is associated with haplotype 1121221 on the paternal chromosome, and with haplotype 1221221 on the maternal chromosome, as defined by the markers met D/TaqI, met H/TaqI, G2/XbaI, XV2C/TaqI, KM19/PstI, D9/MspI, and J3.11/MspI.

The stop mutation G542X is predicted to result in decreased levels of mutant messenger RNA¹² and in a truncated CFTR protein from NBD-1,¹ suppressing 63% of the molecule. However, the homozygous patients for G542X previously reported had mild pulmonary disease,^{3-5,10} which would imply alternative splicing mechanisms suppressing the effect of the stop mutation in some tissues. Contrasting with these reports, we present the second case of a child homozygous for G542X with severe pancreatic and lung disease. Another similar finding has just been reported in a Turkish boy in the neonatal period by Bienvenu *et al.*¹³ Such contradictions in genotype/phenotype correlations might be resolved in the future by mRNA and protein expression studies in target tissues.

We wish to express our gratitude to the Association Française de Lutte contre la Mucoviscidose (AFLM). The manuscript was typed by T Bousquet.

MARIE DESGEORGES
MAGUELONE LAUSSEL
BERNARD ROLLIN
JACQUES DEMAILLE
MIREILLE CLAUSTRES
Laboratoire de Biochimie Génétique,
CNRS UPR-9008,
CRBM U249 and GREPAM,
Institut de Biologie,
Bd Henri IV,
34060 Montpellier, France.

- 1 Kerem B, Zielenski J, Markiewicz D, *et al.* Identification of mutations in regions corresponding to the 2 putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. *Proc Natl Acad Sci USA* 1990;87:8447-51.
- 2 Claustres M, Laussel M, Desgeorges M, *et al.* Analysis of the 27 exons and flanking regions of the cystic fibrosis gene: 40 different mutations account for 92.1% of the mutant alleles in Southern France. *Hum Mol Genet* 1993;2:1209-13.
- 3 Bonduelle M, Lissens W, Liebaers I, *et al.* Mild cystic fibrosis for G542 non-sense mutation in CF gene. *Lancet* 1991;338:189.
- 4 Beaudet AL, Perciaccante RG, Cutting GR. Homozygous nonsense mutation causing cystic fibrosis with uniparental disomy. *Am J Hum Genet* 1991;48:1213.
- 5 Cuppens H, Marynen P, De Boeck C, *et al.* A child, homozygous for a stop codon in exon 11, shows milder cystic fibrosis symptoms than her heterozygous nephew. *J Med Genet* 1990;27:717-19.
- 6 Gasparini P, Borgo G, Mastella G, *et al.* Nine cystic fibrosis patients homozygous for the CFTR nonsense mutation R1162X have mild or moderate lung disease. *J Med Genet* 1992;29:558-62.
- 7 Bal J, Struhmann M, Schloesser M, *et al.* A cystic fibrosis patient homozygous for the nonsense mutation R553X. *J Med Genet* 1991;28:715-17.

- 8 Cheadle J, Al-Jader L, Goodchild M, Meredith AL. Mild pulmonary disease in a cystic fibrosis child homozygous for R553X. *J Med Genet* 1992;29:597.
- 9 Cutting G, Kalsch LM, Rosenstein BJ, *et al.* A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. *Nature* 1990;346:366-9.
- 10 Kalaydjieva L, Angelicheva D, Galeva I, *et al.* Cystic fibrosis in Bulgaria. *J Med Genet* 1991;28:807.
- 11 Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. *Genomics* 1989;5:874-9.
- 12 Daar J, Maquat L. Premature translation termination mediates triosephosphate isomerase mRNA degradation. *Mol Cell Biol* 1988;8:802-13.
- 13 Bienvenu T, Beldjord C, Fonknechten N, *et al.* Severe cystic fibrosis in a child homozygous for the G542 nonsense mutation in the CFTR gene. *J Med Genet* 1993;30:621-4.

Cutis laxa: a feature of Costello syndrome

We were extremely interested to read the letter 'Cutis laxa and the Costello syndrome',¹ in which the authors review case 5 of their previous paper describing children with cutis laxa² and make a diagnosis of Costello syndrome. Recently, and independently, we have reviewed case 7 from the same paper and on both history and clinical examination made an unequivocal diagnosis of Costello syndrome.³

Now that two separate cases within this subgroup of congenital cutis laxa with retardation of growth and development have been independently diagnosed as Costello syndrome, it is obviously time for a review of this heterogeneous group and recognition of this syndrome as a differential diagnosis in congenital cutis laxa, especially in the presence of postnatal growth retardation and delayed development.

SARAH J DAVIES
HELEN E HUGHES
Institute of Medical Genetics,
University of Wales College of Medicine,
Heath Park,
Cardiff CF4 4XW, UK.

- 1 Patton MA, Baraitser M. Cutis laxa and the Costello syndrome. *J Med Genet* 1993;30:622.
- 2 Patton MA, Tolmie J, Ruthum P, Bamforth S, Baraitser M, Pembrey M. Congenital cutis laxa with retardation of growth and development. *J Med Genet* 1987;24:556-61.
- 3 Martin RA, Lyons Jones K. Delineation of the Costello syndrome. *Am J Med Genet* 1991;41:346-9.

Fibrodysplasia ossificans progressiva

I read with interest the article by Connor *et al.* 'A three generation family with fibrodysplasia ossificans progressiva' (*J Med Genet* 1993;30:687-9). In the article, hip synovial osteochondromatosis was described and was said never to have been reported previously in FOP. In fact, Kalifa *et al.* described this finding in *Pediatric Radiology* (1993;23:91-3) in an article entitled 'Fibrodysplasia ossificans progressiva and synovial chondromatosis in 10 and 15 year old patients'. Given these reports perhaps synovial chondromatosis deserves to be considered a feature of FOP.

THOMAS E HERMAN
Department of Radiology,
Washington University Medical Center,
St Louis Children's Hospital,
One Children's Place,
St Louis, Missouri 63110-1077, USA.

Low segregation ratios in autosomal recessive disorders

I read with interest the article by Bunday and Young¹ on possible causes for low segregation ratios in autosomal recessive (AR) disorders. They hypothesise on possible mechanisms and explanations concerning the low segregation ratio in cartilage-hair hypoplasia (CHH) found in Finland.² I would like to add some further thoughts and possibilities to the behavioural, methodological, and biological factors that were described in their paper.¹

(1) Parents may decide to refrain from having further children, "even in the absence of genetic counselling".¹ This implies that with improvement of clinical genetic facilities, proper early genetic diagnosis, and adequate, non-directive counselling, segregation ratios in AR disorders will in future be even lower. As a result of this, we may then actually be measuring an effect of counselling upon parents' behaviour instead of bona fide biological mechanisms. It will then be difficult to find unbiased, that is, uncounselled, populations.

(2) Pregnancies which have been terminated after prenatal diagnosis will also have to be taken into account for the purpose of accurate ascertainment.

(3) Reduced penetrance in CHH has been found in both of the published population studies.^{2,3} In contrast to Mäkitie,² Sulisalo *et al.*³ found no evidence of reduced penetrance in Finnish CHH families. However, their conclusion was based on 14 small families selected for linkage analysis, where the proportion of affected sibs (after exclusion of the probands) was 0.38. The chance of finding even more (non-penetrant) affected sibs is unlikely, given the already high segregation ratio in this sample, and so the question of reduced penetrance is still open.

(4) McKusick *et al.*³ in their original paper, put forward environmental factors as a hypothetical cause of reduced penetrance and a low segregation ratio in CHH: either the homozygous phenotype is corrected by some normal dietary constituent or the homozygous phenotype becomes evident only in combination with some environmental factor. Although they refer to two X linked disorders to illustrate this possibility (G6PD deficiency and vitamin D resistant rickets³), environmental factors could also hypothetically lower the segregation ratio in AR disorders.

(5) Apparent reduced penetrance may partly be the result of ascertainment bias, since in most of the studies undertaken, short stature and x ray abnormalities were the main criteria for diagnosis.²⁻⁶ But, in addition, variable expression, although uncommon in most AR disorders, may also cause a low segregation ratio. The occurrence of mild immunodeficiency without dwarfism has been described in CHH.⁷ However, in most studies only short statured CHH patients have been checked for immunodeficiency,²⁻⁶ with the exception of one in which sibs were used as controls.⁸ Therefore CHH patients with only mild immunodeficiency could have been missed, thereby skewing the number of affected sibs.

The well known increased risk of intrauterine lethality in several AR disorders, though not in CHH,¹ can be considered to be the most severe end of this spectrum of variability. Also the intrafamilial heterogeneity of cystic fibrosis, perhaps because of other modifying loci,⁹ makes it plausible that